Vantage logo

The Cytomx paradox

Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.

Vantage logo

Sarepta loses its Momentum

A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.